Prognostic and treatment response predictive method

Patent metadata

Field	Value
Publication number	US-11788148-B2
Application number	US-201816755085-A
Country	US
Kind code	B2
Filing date	Oct 12, 2018
Priority date	Oct 12, 2017
Publication date	Oct 17, 2023
Grant date	Oct 17, 2023

Abstract

The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

First claim

The invention claimed is:

1. A method of treatment of gastroesophageal cancer in a human patient, said patient having had at least one perioperative treatment with one or more chemotherapeutic agents and having had surgical resection of a gastroesophageal tumour, the method comprising:
(a) measuring the gene expression of at least the genes CDH1, ELOVL5, EGFR, PIP5K1B, FGF1, CD44 and TBCEL in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes CDH1, ELOVL5, EGFR, PIP5K1B, FGF1, CD44 and TBCEL; and
(b) deriving a risk score by weighting the measured, and optionally normalised, expression level of each gene and summing the weighted expression level of each of the genes, wherein the contribution to the total risk score made by CD44 and EGFR has the opposite sign to that of the contribution made by CDH1, ELOVL5, PIP5K1B, FGF1 and TBCEL;
(c) determining from said score that the patient is at high or moderate risk of poor prognosis; and
(d) following said determining administering therapy to the patient a therapeutically effective amount of at least one chemotherapeutic agent selected from the group consisting of epirubicin, cisplatin, 5-fluorouracil, capecitabine, oxaliplatin, and docetaxel.

Assignees

• The Institute Of Cancer Res Royal Cancer Hospital
• The Royal Marsden Nhs Found Trust
• Nat Univ Singapore

Inventors

• Smyth Elizabeth
• Sadanandam Anguraj
• Nyamundanda Gift
• Cunningham David
• Tan Boon Ooi Patrick

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/158

  Expression markers · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title